Physician profile
Christopher J Oldfield
NPI 1073512877
$11,053.13
in general payments reported to CMS, 2019-2025
67 companies · $1,374 in 2025
The $1,374 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,819 · 2020: $1,306 · 2021: $1,819 · 2022: $1,528 · 2023: $1,930 · 2024: $1,278 · 2025: $1,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,581.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,151.99 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $933.80 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Novartis Pharmaceuticals Corporation | $831.86 | 2019-2025 | |
| Novo Nordisk INC | $825.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $767.50 | 2021-2025 | |
| Lilly USA, LLC | $751.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $682.52 | 2019-2025 | |
| Esperion Therapeutics, INC. | $631.29 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $620.32 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $421.85 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $357.36 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Teva Pharmaceuticals USA, INC. | $276.86 | 2019-2024 | Austedo Xr, Ajovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.18 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $191.83 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $181.44 | 2019-2020 |
Show all 60 companies
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Oldfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.